ahlam1399
07-22-2015, 08:21 PM
Biogen Alzheimer?s drug data falls flat, Lilly gets slight bump
July 22 (Reuters) - Disappointing data for Biogen Inc's experimental Alzheimer's drug dragged shares in the company lower on Wednesday, while investors took a slightly more positive view of new findings for a treatment from Eli Lilly and Co.
http://rc.feedsportal.com/r/234565917770/u/49/f/654213/c/35217/s/48581c91/sc/21/rc/1/rc.img (http://rc.feedsportal.com/r/234565917770/u/49/f/654213/c/35217/s/48581c91/sc/21/rc/1/rc.htm)
http://rc.feedsportal.com/r/234565917770/u/49/f/654213/c/35217/s/48581c91/sc/21/rc/2/rc.img (http://rc.feedsportal.com/r/234565917770/u/49/f/654213/c/35217/s/48581c91/sc/21/rc/2/rc.htm)
http://rc.feedsportal.com/r/234565917770/u/49/f/654213/c/35217/s/48581c91/sc/21/rc/3/rc.img (http://rc.feedsportal.com/r/234565917770/u/49/f/654213/c/35217/s/48581c91/sc/21/rc/3/rc.htm)
http://da.feedsportal.com/r/234565917770/u/49/f/654213/c/35217/s/48581c91/sc/21/a2.img (http://da.feedsportal.com/r/234565917770/u/49/f/654213/c/35217/s/48581c91/sc/21/a2.htm)
http://adchoice.feedsportal.com/r/234565917770/u/49/f/654213/c/35217/s/48581c91/sc/21/ach.img (http://adchoice.feedsportal.com/r/234565917770/u/49/f/654213/c/35217/s/48581c91/sc/21/ach.htm)http://pi.feedsportal.com/r/234565917770/u/49/f/654213/c/35217/s/48581c91/sc/21/a2t.imghttp://pi2.feedsportal.com/r/234565917770/u/49/f/654213/c/35217/s/48581c91/sc/21/a2t2.imghttp://i1.wp.com/reuters.us.feedsportal.com/c/35217/f/654213/s/48581c91/sc/21/mf.gif?resize=1%2C1 http://feeds.feedburner.com/~ff/reuters/companyNews?d=yIl2AUoC8zA (http://feeds.reuters.com/~ff/reuters/companyNews?a=f2Ga8yU-dLU:8YZxq80LSUo:yIl2AUoC8zA) http://feeds.feedburner.com/~ff/reuters/companyNews?i=f2Ga8yU-dLU:8YZxq80LSUo:V_sGLiPBpWU (http://feeds.reuters.com/~ff/reuters/companyNews?a=f2Ga8yU-dLU:8YZxq80LSUo:V_sGLiPBpWU) http://feeds.feedburner.com/~ff/reuters/companyNews?i=f2Ga8yU-dLU:8YZxq80LSUo:F7zBnMyn0Lo (http://feeds.reuters.com/~ff/reuters/companyNews?a=f2Ga8yU-dLU:8YZxq80LSUo:F7zBnMyn0Lo)
http://feeds.feedburner.com/~r/reuters/companyNews/~4/f2Ga8yU-dLU
July 22 (Reuters) - Disappointing data for Biogen Inc's experimental Alzheimer's drug dragged shares in the company lower on Wednesday, while investors took a slightly more positive view of new findings for a treatment from Eli Lilly and Co.
http://rc.feedsportal.com/r/234565917770/u/49/f/654213/c/35217/s/48581c91/sc/21/rc/1/rc.img (http://rc.feedsportal.com/r/234565917770/u/49/f/654213/c/35217/s/48581c91/sc/21/rc/1/rc.htm)
http://rc.feedsportal.com/r/234565917770/u/49/f/654213/c/35217/s/48581c91/sc/21/rc/2/rc.img (http://rc.feedsportal.com/r/234565917770/u/49/f/654213/c/35217/s/48581c91/sc/21/rc/2/rc.htm)
http://rc.feedsportal.com/r/234565917770/u/49/f/654213/c/35217/s/48581c91/sc/21/rc/3/rc.img (http://rc.feedsportal.com/r/234565917770/u/49/f/654213/c/35217/s/48581c91/sc/21/rc/3/rc.htm)
http://da.feedsportal.com/r/234565917770/u/49/f/654213/c/35217/s/48581c91/sc/21/a2.img (http://da.feedsportal.com/r/234565917770/u/49/f/654213/c/35217/s/48581c91/sc/21/a2.htm)
http://adchoice.feedsportal.com/r/234565917770/u/49/f/654213/c/35217/s/48581c91/sc/21/ach.img (http://adchoice.feedsportal.com/r/234565917770/u/49/f/654213/c/35217/s/48581c91/sc/21/ach.htm)http://pi.feedsportal.com/r/234565917770/u/49/f/654213/c/35217/s/48581c91/sc/21/a2t.imghttp://pi2.feedsportal.com/r/234565917770/u/49/f/654213/c/35217/s/48581c91/sc/21/a2t2.imghttp://i1.wp.com/reuters.us.feedsportal.com/c/35217/f/654213/s/48581c91/sc/21/mf.gif?resize=1%2C1 http://feeds.feedburner.com/~ff/reuters/companyNews?d=yIl2AUoC8zA (http://feeds.reuters.com/~ff/reuters/companyNews?a=f2Ga8yU-dLU:8YZxq80LSUo:yIl2AUoC8zA) http://feeds.feedburner.com/~ff/reuters/companyNews?i=f2Ga8yU-dLU:8YZxq80LSUo:V_sGLiPBpWU (http://feeds.reuters.com/~ff/reuters/companyNews?a=f2Ga8yU-dLU:8YZxq80LSUo:V_sGLiPBpWU) http://feeds.feedburner.com/~ff/reuters/companyNews?i=f2Ga8yU-dLU:8YZxq80LSUo:F7zBnMyn0Lo (http://feeds.reuters.com/~ff/reuters/companyNews?a=f2Ga8yU-dLU:8YZxq80LSUo:F7zBnMyn0Lo)
http://feeds.feedburner.com/~r/reuters/companyNews/~4/f2Ga8yU-dLU